Surgical treatment of liver metastases of gastric cancer: state of the art

World Journal of Surgical Oncology

Franco Uggeri¹  Angelo Nespoli¹  Luca Gianotti¹  Luca Nespoli¹  Luca Degrate¹  Fabio Uggeri¹  Mattia Garancini¹  Fabrizio Romano¹ 

[1]Department of Surgery, San Gerardo Hospital- University of Milano Bicocca, Via Donizetti 106, Monza 20052, Italy

关键词: Prognosis;    Metastases;    Liver resection;    Gastric cancer;   

Others  :  827438
DOI  :  10.1186/1477-7819-10-157

 received in 2011-08-29, accepted in 2012-06-21,  发布年份 2012

【 摘 要 】

Background

The prognosis of patients with liver metastases from gastric cancer (LMGC) is dismal, and little is known about prognostic factors in these patients; so justification for surgical resection is still controversial. Furthermore the results of chemotherapy for these patients are disappointing. The purpose of this study was to review recent outcomes of hepatectomy for LMGC and to determine the suitable candidates for surgery, assessing the surgical results and clinicopathologic features. Moreover we compare these results with those obtained with alternative treatments.

【 授权许可】

   
2012 Romano et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Jernal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics 2009. CA cancer J Clin 2009, 59:225-249.
• [2]Jl D, van de Velde CJ, Coit DG, Shah MA, Verheij M, Cats A: Treatment of resectable gastric cancer. Therap Adv Gastroenterol 2012, 5:49-69.
• [3]Shin A, Kim J, Park S: Gastric cancer epidemiology in Korea. J Gastric Cancer 2011, 11:135-140.
• [4]Schlansky B, Sonnemberg A: Epidemiology of noncardia gastric adenocarcinoma in the United States. Am J Gastroenterol 2011, 106:1978-1985.
• [5]Kemeny N: Management of liver metastases from colorectal cancer. Oncology 2006, 20:1161-1176.
• [6]Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, Yamamoto J, Imamura H: Extension of the frontiers of surgical indication in the treatment of liver metastases from colorectal cancer. Ann Surg 2000, 231:487-499.
• [7]Primrose JN: Surgery for colorectal liver metastases. Br J Cancer 2010, 102:1313-1318.
• [8]Shirabe K, Wakiyama S, Gion T, Watanabe M, Miyazaki M, Yoshinaga K, Tokunaga M, Nagaie T: Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature. HPB 2006, 8:89-92.
• [9]Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Yoshidome H, Shimizu Y, Nakajima N: Benefits and limits of hepatic resection for gastric metastases. Am J Surg 2001, 181:279-283.
• [10]Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-318.
• [11]Kakeji Y, Morita M, Maehara Y: Strategies for treating liver metastases from gastric cancer. Surg Today 2010, 40:287-294.
• [12]Ueda K, Iwahashi M, Nakamori M, Nakamura M, Naka T, Ishida K, Ojima T, Yamaue H: Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg 2009, 394:647-653.
• [13]Fujisaki S, Tomita R, Nezu T, Kimizuka K, Park E, Fukuzawa M: Prognostic studies on gastric cancer with concomitant liver metastases. Hepatogastroenterology 2001, 48:802-804.
• [14]Linhares E, Monteiro M, Kesley R, Santos CE, Filho OS, Simoes JH: Major hepatectomy for isolated metastases from gastric adenocarcinoma. HPB 2003, 5:235-237.
• [15]Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M: Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 1995, 71:587-591.
• [16]Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenlam M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E, V-325 Study Group: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastro-oesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007, 25:3205-3209.
• [17]Yoshida M, Ohtsu A, Boku N, Miyata Y, Shirao K, Shimada Y, Hyodo I, Koizumi W, Kurihara M, Yoshida S, Yamamoto S: Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol 2004, 34:654-659.
• [18]Cocconi G, Carlini P, Gamboni A, Gasperoni S, Rodinò C, Zironi S, Bisagni G, Porrozzi S, Cognetti F, Di Costanzo F, Canaletti R, Ruggeri EM, Camisa R, Pucci F: For the Italian Oncology Group for Clinical Research. Cisplatin, epirubicin, leucovorin and 5-fluorourail (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 2003, 14:1258-1263.
• [19]Lee J, Kang WK, Kwon JM, Oh SY, Lee HR, Kim HJ, Park BB, Lim HY, Han MJ, Park JO, Park YS: Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol 2007, 18:88-92.
• [20]Cao W, Yang W, Lou G, Jilang J, Geng M, Xi W, Li H, Ma T, Jin Y: Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. Anticancer Drugs 2009, 20:287-293.
• [21]Liu J, Chen L: Current status and progress in gastric cancer with liver metastases. Chin Med J 2011, 124:445-456.
• [22]Baba H, Okuyama T, Hiroyuki O, Anai H, Korenaga D, Maehara Y: Prognostic factors for noncurative gastric cancer: univariate and multivariate analysis. J Surg Oncol 1992, 51:104-108.
• [23]Imamura H, Matsuyama Y, Shimada R, Kubota M, Nakayama A, Kobayashi A, Kitamura H, Ikegami T, Miyagawa S, Kawasaki S: A study of factors influencing prognosis after resection of hepatic metastases from colorectal and gastric carcinoma. Am J Gastroenterol 2001, 96:3178-3184.
• [24]Thelen A, Jonas S, Benckert C, Lopez-Hänninen E, Neumann U, Rudolph B, Schumacher G, Neuhaus P: Liver resection for metastatic gastric cancer. Eur J Surg Oncol 2008, 34:1328-1334.
• [25]Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, Kokudo N, Yamaguchi T, Muto T, Makuuchi M: Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery 2003, 133:507-511.
• [26]Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, Jaeck D, Saric J, Le Treut YP, Belghiti J, Mantion G, Mentha G: For the Association Française de Chirurgie. Hepatic resection for noncolorectal nonendocrine liver metastases. Ann Surg 2006, 244:524-535.
• [27]Kerkar SP, Kemp CD, Avital I: Liver resections in metastatic gastric cancer. HPB 2010, 12:589-596.
• [28]Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, Usuki H, Maeta H: Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002, 235:86-91.
• [29]Roh HR, Suh KS, Lee HJ, Yang HK, Choe KJ, Lee KU: Outcome of hepatic resection for metastatic gastric cancer. Am Surg 2005, 71:95-99.
• [30]Ochiai T, Sasako M, Mizuno S, Kinoshita T, Takayama T, Kosuge T, Yamazaki S, Maruyama K: Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors. Br J Surg 1994, 81:1175-1178.
• [31]Saiura A, Umekita N, Inoue S, Maeshiro T, Miyamoto S, Matsui Y, Asakage M, Kitamura M: Clinicopathological features and outcome of hepatic resection for liver metastases from gastric cancer. Hepatogastroenterology 2002, 49:1062-1065.
• [32]Japanese Gastric Cancer association: Japanese classification of gastric carcinoma. 2nd English edition. Gastric Cancer 1998, 1:10-24.
• [33]Zacherl J, Zacherl M, Scheuba C, Steininger R, Wenzl E, Muhlbacher F, Jakesz R, Langle F: Analysis of hepatic resection of metastases originating from gastric adenocarcinoma. J Gastrointest Surg 2002, 6:682-689.
• [34]Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Yasuyuki S, Yamaguchi T: Liver resection for metastatic gastric cancer: experience with 42 patients including 8 long-term survivors. Jpn J Clin Oncol 2007, 37:836-842.
• [35]Kwak CM, Wu CW, Lo SS, Shen KH, Hsieh MC, Lui WY: Survival of gastric cancer with concomitant liver metastases. Hepatogastroenterology 2004, 51:1527-1530.
• [36]Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, Plaud B, Ducreux M, Spielmann M, Theodore C, Bonvalot S, Lasser P: Resection of liver metastases from a non-colorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 1998, 187:487-493.
• [37]Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, Ahn JB, Roh JK, Noh SH, Chung HC: Survival benefit of combined curative resection of the stomach and liver in gastric cancer patients with liver metastases. Ann Oncol 2008, 19:1153-1158.
• [38]Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993, 71:3813-3818.
• [39]Bines SD, England G, Deziel DJ, Witt TR, Doolas A, Roseman DL: Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors. Surgery 1993, 114:799-805.
• [40]Morise Z, Sugioka A, Hoshimoto S, Kato T, Ikeda M, Uyama I, Horiguchi A, Miyakawa S: The role of hepatectomy for patients with liver metastases of gastric cancer. Hepatogastroenterology 2008, 55:1238-1241.
• [41]Shirabe K, Shimada M, Matsumata T, Higashi H, Yakeishi Y, Wakiyama S, Ikeda Y, Ezaki T, Fukuzawa S, Takenaka K, Kishikawa K, Ikeda T, Taguchi K, Maehara Y, Sugimachi K: Analysis of the prognostic factors for liver metastases of gastric cancer after hepatic resection. A multi-insitutional study of the indications for resection. Hepatogastroenterology 2003, 50:1560-1563.
• [42]Tsujimoto H, Ichikura T, Ono S, Sugasawa H, Hiraki S, Sakamoto N, Yaguchi Y, Hatsuse K, Yamamoyo J, Hase K: Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int 2010, 4:406-413.
• [43]Miyazaki M, Itoh H, Nakagawa K, Ambiru S, Shimizu H, Togawa A, Shiobara M, Ohtsuka M, Sasada K, Shimizu Y, Yoshioka S, Nakajima N, Suwa T, Kimura F: Hepatic resection of liver metastases from gastric adenocarcinoma. Am J Surg 1997, 92:490-493.
• [44]Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, Katai H, Kosuge T, Sasako M: Favorable indications for hepatectomy in patients with liver metastases from gastric cancer. J Surg Oncol 2007, 95:534-539.
• [45]Fujii K, Fujioka S, Kato K, Machici Y, Kutsuna Y, Ishikawa A, Takamizawa J, Ko K, Yoshida K, Nimura Y: Resection of liver metastases from gastric adenocarcinoma. Hepatogastroenterology 2001, 48:368-371.
• [46]Romano F, Cesana G, Caprotti R, Bovo G, Uggeri F, Piacentini MG, Crippa S, Uggeri F: Pre-operative IL-2 immunotherapy enhances tumor inflitrating Lymphocytes (TILs) in gastric cancer patients. Hepatogastroenterology 2006, 53:634-638.
• [47]Nomura T, Kamio Y, Takasu N, Moriya T, Takeshita A, Mizutani M, Hachiya O, Hirai I, Kimura W: Intrahepatic micrometastases around liver metastases from gastric cancer. J Hepatobiliary Pancreas Surg 2009, 16:493-501.
• [48]Isono T, Miyazaki M, Udagawa I, Koshikawa H, Iimura M, Itoh H: The clinicopathological study of intrahepatic micrometastases in hepatic metastases carcinoma: comparison between hepatic metastases from gastric cancer and colorectal cancer. J Jpn Soc Cancer Ther 1992, 27:893-899.
• [49]Makino H, Kunisaki C, Izumisawa Y, Tokuhisa M, Oshima T, Nagano Y, Fujii S, Kimura J, Takagawa R, Kosaka T, Ono HA, Akiyama H, Tanaka K, Endo I: Indication for hepatic resection in the treatment of liver metastasis from gastric cancer. Anticanc Res 2010, 30:2367-2376.
• [50]Ueda K, Iwahashi M, Nakamori M, Nakamura M, Naka T, Ishida K, Ojima T, Yamaue H: Analysis of the prognostic factors and evaluation of sirgical treatment for synchronous liver metastases from gastric cancer. Langenbeks Arch Surg 2009, 394:647-653.
• [51]Tiberio GAM, Coniglio A, Marchet A, Marrelli D, Giacopuzzi S, Baiocchi L, Roviello F, de Manzoni G, Nitti D, Giulini SM: Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. EJSO 2009, 35:486-491.
• [52]Hwang S-E, Yang D-H, Kim C-Y: Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer. World J Surg 2009, 33:1468-1472.
• [53]Yamakado K, Nakatsuka A, Takaki H, Mori Y, Tonouchi H, Kusunoki M, Kida H, Takeda K: Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer. J Vasc Interv Radiol 2005, 16:1747-1751.
• [54]Kim HO, Hwang SI, Hong HP, Yoo CH: Radiofrequency ablation for metachronous hepatic metastases from gastric cancer. Surg Laparosc Endosc Percutan Tech 2009, 19:208-212.